BUSINESSThe Dales Report
The Dales Report examines High Tide growth and Schedule III compliance
The Dales Report reviewed High Tide's record third-quarter revenue and asset-light U.S. ambitions, then discussed Schedule III operational issues including DEA registration, product consistency, drug-interaction screening and the limits of automatic insurance coverage. Oklahoma operators get both a competitive public-company signal and a practical checklist for medical-market compliance planning.
Published Oct 1, 2026
Read the full article at The Dales Report#national#capital#rescheduling#compliance#medical-cannabis#market-data
Read the original source
Leafy summaries provide industry context. Confirm details with The Dales Report.